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For decades, lung cancer has been the most common cancer in terms of both
incidence and mortality. There has been very little improvement in the prognosis of
lung cancer. Early treatment following early diagnosis is considered to have potential
for development. The National Lung Screening Trial (NLST), a large, well-designed
randomized controlled trial, evaluated low-dose computed tomography (LDCT) as a
screening tool for lung cancer. Compared with chest X-ray, annual LDCT screening
reduced death from lung cancer and overall mortality by 20 and 6.7 %, respectively,
in high-risk people aged 55–74 years. Several smaller trials of LDCT screening are
under way, but none are sufficiently powered to detect a 20 % reduction in lung
cancer death. Thus, it is very unlikely that the NLST results will be replicated. In addition,
the NLST raises several issues related to screening, such as the high false-positive rate,
overdiagnosis and cost. Healthcare providers and systems are now left with the question
of whether the available findings should be translated into practice. We present the main
reasons for implementing lung cancer screening in high-risk adults and discuss the main
issues related to lung cancer screening. We stress the importance of eligibility criteria,
smoking cessation programs, primary care physicians, and informed-decision making
should lung cancer screening be implemented. Seven years ago, we were waiting for the
results of trials. Such evidence is now available. Similar to almost all other cancer screens,
uncertainties exist and persist even after recent scientific efforts and data. We believe that
by staying within the characteristics of the original trial and appropriately sharing the
evidence as well as the uncertainties, it is reasonable to implement a LDCT lung cancer
screening program for smokers and former smokers.
Keywords: Lung cancer, Screening, Low dose computed tomography, Overdiagnosis,
Smoking, Evidence, ImplementationIntroduction
In 2007, we discussed the situation and perspective of lung cancer screening [1]. At
that time, we presented the high mortality of lung cancer, described the promising
screening modalities, and characterized the ongoing and planned trials. Overall, we
concluded that until the completion of these trials, widespread lung cancer screening
intervention should be avoided. Eight years and a large randomized clinical trial (RCT)
later, we propose to discuss why and how we would implement a lung cancer screening
program, if any. In this narrative review, we briefly review the current evidence regard-
ing the influence of lung cancer screening on lung cancer mortality as well as the
major issues and limitations related to lung cancer screening. We then discuss the© 2015 Guessous and Cornuz. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in
any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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cancer screening program.
Why would we implement a lung cancer screening program?
Several reasons can motivate the implementation of a lung cancer screening program.
These reasons include the decade-long burden of lung cancer, the lack of meaningful
improvement in lung cancer prognosis, the identification of a well-defined population
at high risk of lung cancer, and the evidence from a large, well-designed RCT.
Burden of lung cancer
Lung cancer represents a huge public health burden. Worldwide, it is the leading cause of
death from cancer, with 1.6 million deaths reported each year [2]. It affects both males
and females, in which it is either the first or second (respectively) leading cause of death
from cancer [3]. In fact, lung cancer causes more deaths than do colorectal, breast, and
prostate cancer combined [1].
A remarkable observation that contrasts with other frequent cancers in adults is that
the 5-year survival rate of lung cancer remains –in 2015— very low. In developed coun-
tries, the overall 5-year survival rate is 20 % or less [4]. This is because lung cancer is gen-
erally diagnosed at late stages, when treatments do not improve the prognosis. The poor
chance of cure at late stages of lung cancer contrasts with the 80 % 5-year survival rate
observed when treatment is initiated at an early stage [5].
Although mortality trends differ between countries, even within the European region
(Fig. 1), this grim situation has existed for decades, and novel treatment modalities that
could improve the 5-year survival rate of lung cancer are not well established [6].Fig. 1 Lung cancer mortality in selected countries in the European region 1970–2014 (data from the Health
for All Data Base, World Health Organization, European Region, 2014, courtesy of TH Tulchinsky). Footnote:
SDR, standardized death rate
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Screening is considered legitimate in the presence of a frequent disease that is generally
diagnosed too late for treatment to be curative [7, 8]. Screening might be planned when
a population at risk has been clearly identified. Smoking is the primary cause of lung
cancer, and population variation in lung cancer incidence and mortality clearly reflects
smoking behavior [9]. Compared with never smokers, smokers have a 20-fold increased
risk of dying from lung cancer [10]. There is a decreasing but persistent risk among
former smokers, at least within the 15 years after quitting [11].
Evidence regarding lung cancer screening intervention
Until recently, there was no recommended screening strategy for lung cancer, reflecting
the negative results of trials showing no mortality reduction following screening pro-
grams using chest X-ray and sputum examination (for a review see [1]). The Prostate,
Lung, Colorectal, and Ovarian Cancer Screening (PLCO) trial was the first large RCT
conducted to determine the effectiveness of annual lung cancer screening by chest X-
ray [12]. It was conducted in the US and randomized 154,900 participants aged 55–74
years to annual chest X-ray screening or usual care for 4 years with 13 years of follow-
up. Annual chest X-ray screening did not reduce lung cancer mortality compared with
usual care [5, 12].
The development of fast, high-resolution computed tomography (CT) scans allows
the acquisition of multiple slice images within a single breath hold by the patient. With
multiple images, the 3-dimensional shape of small nodules can be characterized [13].
Diagnostic CT scan examination uses 200 milliampere seconds (mAs), but a lower dose
(approximately 60 mAs) can be used for screening purposes. Imaging with this low-
dose CT (LDCT) is of lower quality than with full dose CT, but it is better than images
provided by chest X-ray. The first evaluations of LDCT as a screening tool were done
in observational (i.e., non-experimental) studies, and they have been summarized previ-
ously [1]. Because of their potential biases, observational studies are of limited use
when trying to determine the effectiveness of lung cancer screening (and more gener-
ally when trying to determine the effectiveness of one treatment or test over another).
RCTs –the supreme paradigm for epidemiological research—are needed [14]. Several
LDCT lung cancer screening RCTs have been conducted or are ongoing, but the
National Lung Screening Trial (NLST) [15] was and will likely remain the largest RCT
to examine the effectiveness of such screening at reducing death from lung cancer [16].
The NLST, the main results of which were published in 2011 and in subsequent ana-
lyses in 2013, is the largest and most expensive (>$200 million) RCT conducted in the
US for a single cancer screen [17]. The main characteristics and results of the NLST
are presented in Table 1 and briefly discussed below.
From August 2002 through April 2004, 53,454 participants were randomly assigned
to annual LDCT lung cancer screening scans versus chest X-ray for three consecutive
years in 33 different sites. The eligible participants were high-risk people, defined as
adults aged 55–74 years who had smoked at least 30 pack years or former smokers
who had quit 15 years ago or less. The NLST participants appeared to be younger,
more educated, and more frequently former smokers than the comparable US eligible
population [18, 19]. Adherence to screening was very high (93 %) in both arms [20]. In
the case of positive findings (i.e., LDCT arm: at least one noncalcified nodule ≥4 mm in
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any noncalcified nodule or mass), decisions about how to proceed were left to the refer-
ring physician [2].
The incidence of lung cancer was 645 cases per 100 000 person years (1060 cancers)
in the LDCT group compared with 572 cases per 100 000 person years (941 cancers) in
the chest X-ray arm. In the LDCT screening arm, 356 deaths from lung cancerTable 1 Main characteristics and results of the National Lung Screening Trial (NLST), 33 sites in the
United States
Intervention arm Control arm





Age, years 55 to 74
Smoking status ≥30 pack-years or had been smokers
within the previous 15 years
Screening interval Annually
Screening duration 3 years
Number of participants randomized 26,722 26,732
Male, N (%) 15,770 (59.0) 15,762 (59.0)
Number of participants aged ≥65 years (%) 7,110 (26.6) 7,110 (26.6)
Number of former smokers (%) 13,860(51.9) 13,832 (51.7)
Number of current smokers (%) 12,862 (48.1) 12,900 (48.3)
Year 1 (baseline)
Number screened 26,309 26,035
Positive results (%) 7191 (27.3) 2387 (9.2)
Complete diagnostic follow-up (%) 7049 (98.0) 2348 (98.3)
Thoracotomy (%) 197 (2.8) 96 (4.1)
Had lung cancer (%) 270 (3.8) 136 (5.7)
Year 2
Number screened 24,715 24,089
Positive results (%) 6901 (27.9) 1482 (6.2)
Complete diagnostic follow-up (%) 6740 (97.7) 1456 (98.2)
Thoracotomy (%) 148 (2.2) 44 (3.0)
Had lung cancer (%) 168 (2.4) 65 (4.4)
Year 3
Number screened 24,102 23,346
Positive results (%) 4054 (16.8) 1174 (16.8)
Complete diagnostic follow-up (%) 3913 (96.5) 1149 (97.9)
Thoracotomy (%) 164 (4.2) 44 (3.8)
Had lung cancer (%) 211 (5.2) 78 (6.6)
Overall (Year 1–3)
Number of screening tests 75,126 73,470
Positive results (%) 18,146 (16.8) 5043(16.8)
Complete diagnostic follow-up (%) 17,702 (97.5) 4953 (98.2)
Thoracotomy (%) 509 (2.9) 184 (3.7)
Table 1 Main characteristics and results of the National Lung Screening Trial (NLST), 33 sites in the
United States (Continued)
Had lung cancer (%) 649 (3.6) 279 (5.5)
Death within 60 days after most invasive diagnositc procedure 10 11
Person-years 144,103 143,368
Lung cancer death 356 443
Rate per 100,000 person-years 247/100,000 309/100,000
Overall death 1877 1998
Rate per 100,000 person-years 1302 /100,000 1394/100,000
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person-years) in the chest X-ray arm. After a 6.5-year median follow-up, the trial found
that lung cancer mortality was reduced from 1.7 % in the chest X-ray arm to 1.4 % in
the LDCT arm, a statistically significant relative risk reduction of 20 % (95 % CI, 6.8 to
26.7 %). The trial also showed a statistically significant relative reduction of 6.7 % (95 %
CI, 1.2 to 13.6 %) in overall mortality [15]. LDCT screening translated to three or four
fewer lung cancer deaths per 1000 participants (i.e., an absolute risk reduction of lung
cancer death by three to four per 1,000 individuals screened) [21]. The number needed
to screen to prevent 1 lung cancer death was 320 persons undergoing three annual
LDCTs. In comparison, screening mammography estimates suggest that 465 to 601
women must be screened to save one life [19].
Other (mostly European) published and ongoing LDCT lung cancer screening RCTs
(e.g., Dante; MILD; DLCST; NELSON; Italung; Depiscan; Lusi; UKLS) have been pre-
sented and discussed elsewhere [2, 20, 22]. Spiro SG and Navani N [6] all of the trials
are smaller than the NLST and insufficiently powered to detect a 20 % risk reduction.
The results from pooled analyses will of course be interesting to better define who
should be screened, for how long, and how frequently [20], but even when combined,
these trials will likely not have sufficient statistical power to change the conclusions
drawn from the NLST [16].
Like others, we believe that the NLST provides good (but not replicated) evidence
that LDCT lung cancer screening reduces not only lung cancer mortality but also over-
all mortality. Aside from smoking cessation, which reduces the risk of lung cancer mor-
tality by 50 %, LDCT lung cancer screening is the most efficient intervention to reduce
lung cancer mortality among high-risk individuals. Following several organizations (e.g.,
US Preventive Services Task Force [USPSTF], American Cancer Society [ACS]), we
would recommend LDCT lung cancer screening to eligible adults. However, like many
others [23], we are aware of several issues and questions that the NLST has raised or
has left unanswered, including the false positive rate, overdiagnosis, eligibility criteria,
and cost.
False-positive rate
More than any other cancer screen, LDCT lung cancer screening generates false positives
(i.e., participants who had a positive scan but were not found to have lung cancer). In the
NLST trial, the mean false-positive rate was approximately 28 % (range 3.8–69.0 %, depend-
ing on the trial site) [15]. A systematic review of RCTs and cohort studies found that 20 %
of LDCT screening tests lead to false positive findings [24, 25]. This of course suggests that
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a high rate of false positives both for the participants and for the screening program.
In the NLST, some of the positive tests were not considered to require follow-up, but
13 % of the participants underwent further clinical testing. Among the false positives,
some had bronchoscopy and others underwent needle biopsy. Of the approximately
26,000 participants in the LDCT arm, 16 participants, ten of whom had lung cancer,
died within 60 days after an invasive diagnostic procedure (0.59 %) [15]. Overall the in-
cidence of at least one complication was only 1.4 % in the LDCT arm. Among partici-
pants who did not have cancer, <0.1 % of the positive screening tests led to a major
complication after an invasive procedure [15]. As discussed by Detterbeck et al. [26], it
is important to recognize that some deaths may be unrelated events that happened to
occur after a screening procedure. For instance, in NLST, some deaths were presum-
ably unrelated, as 1.9 and 1.5 per 10,000 occurred within 60 days, respectively, in the
LDCT arm and in the chest X-ray arm when the diagnostic evaluation involved only an
imaging evaluation [26].
These data demonstrate that the risk of major complications from LDCT screening
exists but is very low. Thus, the benefits of LDCT screening seem to outweigh the risk
of lung cancer death in the absence of LDCT screening, though a false-positive result
may be associated with short-term emotional distress that is reversible over time [27].
Yet another related issue is the increased risk associated with radiation exposure. Ion-
izing radiation causes DNA breaks that might lead to cancer. An analysis of data from
15 countries has estimated that up to 3 % of cancer diagnosed to the age of 75 years
may be attributable to diagnostic X-rays, including CT scans [28]. However, the as-
sumptions were subject to considerable uncertainty, and different societies of radiology
have rated the additional lifetime risk for fatal cancer from LDCT as very low [5]. It is
estimated that one death from cancer per 2500 people screened may be caused by radi-
ation from three LDCT screens plus related diagnostic imaging [24]. Given that LDCT
screening resulted in one lung cancer death avoided per 320 persons screened, the ben-
efits of screening outweigh the risks from radiation exposure.
Overdiagnosis
Overdiagnosis in cancer screening is defined as a cancer that does not evolve or even
diminishes or a cancer that progresses so slowly that the patient dies from other causes
without ever having developed cancer symptoms. Ruano-Ravina et al. [29] as stressed
by Ruano-Ravina et al. “overdiagnosis is not just a possibility, it is a fact.” [29] Grannis
FW Jr found little evidence for substantial numbers of overdiagnosed [30], whereas the
USPSTF estimated overdiagnosis to occur in 10-12 % of lung cancers [31], and Patz
et al. used data from the NLST to estimate an overdiagnosis rate with three annual
screens of 16-23 % [32].
In an RCT and in the absence of overdiagnosis, once the trial ends, the number of can-
cer diagnoses should be the same in the intervention and control arms. Persistent excess
cancer in the screening arm suggests overdiagnosis [19]. Evidence of overdiagnosis has
been observed in a number of trials [33], but no RCT has been long enough, given that it
may take 10–15 years for the detection rates in the two arms to equalize [6].
Similar to other cancer screens (e.g., prostate cancer screening), all participants diag-
nosed with lung cancer are theoretically treated so that the natural history of untreated
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for estimating the magnitude of overdiagnosis, is not immune from overdiagnosis.
Cost-effectiveness
Although several cost-effectiveness studies of LDCT lung cancer screening have been
published (with a wide range of conclusions) [34–36], only one was based on the NLST
data. The cost-effectiveness analysis based on NLST data found $81,000 per quality ad-
justed life year gained [37]. This is very similar to other cancer screening programs, in-
cluding mammography and colonoscopy [23, 38, 39]. The eligible population for LDCT
lung cancer screening is very large, and the impact of LDCT lung cancer screening on
healthcare cost is obviously not trivial. Models concluded that if it were implemented na-
tionally in the US, an LDCT screening program for a population of 18 million adults with
a smoking history of at least 30 pack years would lead to an added annual cost of $4.4 bil-
lion for the US healthcare system [34]. This is significant, but such a program i) would
prevent over 18,000 premature deaths per year just in the US [40], ii) would be cost-
effective, and iii) would be the only intervention (with smoking cessation) that provides a
meaningful (20 %) decrease in the risk of lung cancer death. Considered together, this
should probably motivate the implementation of an LDCT lung cancer screening.How would we implement a lung cancer screening program?
Although several experts have stressed that areas of uncertainty exist regarding the
benefits and harms of screening the community at large [16, 21, 40], LDCT lung cancer
screening programs have started in the US. Some institutional experiences have dem-
onstrated that NSLT findings are generalizable and that translation of the lung cancer
screening concept into clinical practice is feasible [41]. A 2013 survey of 19 US sites
(selected best hospitals, top cancer and pulmonary disease centers) found that 79 % of
the sites had a CT screening program [42], 73 % of the screening programs used the
NLST entry criteria, and 93 % included a smoking cessation program. Below, we dis-
cuss why an LDCT lung cancer screening program should indeed be based on the
NLST entry criteria and why it should include a smoking cessation program.
Eligibility criteria
The facts that the eligibility criteria for screening in the NLST apply to <30 % of the lung
cancers in the US [43] and that the NLST participants were healthier and better educated
than the general US population have often fueled calls to redefine the entry criteria for
LDCT lung cancer screening. Lung cancer risk prediction models for determining whom
to screen have been proposed (e.g., The PLCO lung cancer risk calculator, which is avail-
able online at http://www.brocku.ca/lung-cancer-risk-calculator). Some of these models
include information on chronic obstructive pulmonary disease or pulmonary function
(e.g., forced expiratory volume in 1 s, FEV1) [44, 45]. Targeting of LDCT lung cancer
screening according to risk has been motivated by a secondary analysis of the NLST data
showing that the 60 % of participants at highest risk for lung cancer death (based on risk
quintiles) accounted for 88 % of the screening-prevented lung cancer deaths, while the
20 % of NLST participants at lowest risk accounted for only 1 % of prevented lung cancer
deaths [46]. Another secondary analysis of the NLST data compared the outcomes of
screening between Medicare-eligible (aged 65 to 74 years) and younger (aged 55 to
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absolute benefits and harms of screening were greater in the 65 to 74 years group. Be-
cause lung cancer incidence and mortality were higher among participants in the older
group at baseline, they had more to gain from screening [47].
Although developing such models and conducting these secondary analyses are cer-
tainly important to further our understanding of the different impacts of LDCT lung
cancer screening, it is worth noting that the strengths of the initial randomization are
habitually lost in post hoc analyses. It is therefore very difficult to recommend LDCT
lung cancer screening beyond the original NLST trial entry criteria. Age criteria, how-
ever, are often discussed. For example, the USPSTF extended the age limit to 80 based
on microsimulation modeling by the Cancer Intervention and Surveillance Modeling
Network (CISNET) Lung Group [31]. Extending the age is not trivial given that false-
positive rates, complication rates from biopsy of pulmonary nodules, postoperative
mortality, and competing risk for death all increase with age [48]. The benefit-risk ratio
of LDCT screening among adults aged >74 is unknown.
In the absence of additional robust evidence on the benefits of screening when ap-
plied to broader populations, we recommend –like others [40]— that programs limit
the use of LDCT screening to those individuals who meet the NLST eligibility criteria.
Smoking cessation
Smoking is the greatest risk factor for lung cancer, and smoking cessation reduces the risk
of dying from lung cancer by more than 50 % [11]. Two major findings have highlighted
the need to include a smoking cessation program within a lung cancer screening program
(e.g., enrollment in a smoking cessation program at the time of screening). First, screening
for lung cancer has been shown to be a teachable moment for smoking cessation [5]. The
smoking cessation rates in the LDCT studies were four-fold the rate observed in the gen-
eral population (4 % vs 16 %) [2]. Although the probability of subsequent smoking seems
to be inversely associated with the abnormality of the screening result, both the screening
and control arms were more likely to stop smoking compared with the general population
[49]. Furthermore, studies have not shown an increased smoking rate in persons with
negative screening results, indicating that participants are not using negative findings to
continue or resume smoking [5]. Additionally, smoking cessation programs (including
pharmacotherapy for nicotine dependence) are very cost-effective interventions [50], with
costs of $5000 per quality-adjusted life-year [51]. Although robust evidence of the benefi-
cial effect of including a smoking cessation program in an LDCT lung cancer screening
program remain to be gathered, it seems legitimate to enroll smokers in a smoking cessa-
tion program at the time of screening. The feasibility of this approach will depend on the
prevalence of current smokers, which can be low in certain settings.
Frameworks for efficient implementation of lung cancer screening programs have been
published [52, 53]. In addition to suggesting eligibility criteria and the inclusion of smok-
ing cessation programs, the frameworks discuss the screening frequency, screening dur-
ation, nodule algorithm, need for longitudinal registries and standards for certification of
screening centers. In general, the recommendations follow the characteristics of the NLST
trial. We would like to stress two additional factors to be considered when implementing
LDCT lung cancer screening (Fig. 2): involving health care providers and using an
informed-decision making approach.
Fig. 2 Proposed outline for implementing an efficient, low-dose computed tomography lung cancer
screening program
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When cancer screening entry criteria are limited to factors such as age (e.g., colorectal
cancer screening) and gender (e.g., breast cancer screening), participants can be invited
via an existing (non-medical) registry. However, when additional entry criteria such as
smoking history are needed, programs often rely on the medical system (medical system-
based) to contact patients. Lung cancer screening, if implemented, would mostly work
through patients, health care providers including physicians, and, more specifically, pri-
mary care physicians. If primary care physicians are not convinced of the efficacy of the
program and/or are not fully aware of the screening entry criteria, the lung cancer screen-
ing program is unlikely to work. This potential gap between recommendation and imple-
mentation is very reminiscent of other medical-system based screens (e.g., abdominal
aneurysm screening among smokers and former smokers) [54]. As discussed below (in-
formed-decision making), we believe that primary care physicians do not need to be con-
vinced that the benefits of lung cancer screening outweigh the risks (this mainly concerns
the patient), but rather they should be convinced that the program would offer his/her pa-
tient the best care possible would he/she decide to participate. Similar to all cancer
screening programs, lung cancer screening programs need to be of the highest quality.
Medical system-based screening programs such as a lung cancer screening program need
to let the primary care physicians know about their high level of quality. Of note, although
our discussion is focused on primary care physicians, the involvement of other health care
professionals could be more appropriate, depending on the health care system. In fact, a
combination of physicians’ referrals, other health professionals’ referrals and even self-
referrals could be the most efficient and cheapest means to reach out to the eligible popu-
lation to improve screening uptake.
Informed decision making
If a lung cancer screening program has to be implemented, it must utilize an informed
decision-making approach. This requirement is sine qua non given that LDCT lung can-
cer screening does both good and harm and presents uncertainties. Surveys have shown
that health care providers often discuss the pros of screening but seldom discuss the cons
[55]. To better inform patients, guidelines on counseling about the risks and benefits of
lung cancer screening prior to screening have been published [26, 56], and decision aids
are available [55]. For example, to support primary care physicians in the informed con-
sent process, some programs send each qualified patient a 4-page list of frequently asked
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disease has been performed for years without systematic informed- and shared-decision
making approaches. Informed/shared-decision making was only recently introduced into
major health organization screening guidelines [57, 58]. Lung cancer screening has no
choice but to be a perfect application of informed choice [58]. Moreover, the evidence-
based information should consider the participant’s literacy and ethnicity and should be
culturally appropriate.
Concluding remarks
In addition to smoking cessation, the 20 % decrease in lung cancer deaths reported in the
large, well-designed NLST trial represents the greatest progress in lung cancer reduction.
In this review, we present the main reasons for implementing LDCT lung cancer screen-
ing in high-risk adults and discussed the main issues related to LDCT lung cancer screen-
ing. Frameworks for the efficient implementation of lung cancer screening programs are
available. We stress the importance of primary care physicians and informed-decision
making. In 2007, we were waiting for the results of RCTs. Although the only large trial
could not answer all of the questions, evidence is now available. Similar to almost all other
cancer screens, uncertainties exist and persist even after colossal efforts such as the NLST.
However, we believe that while staying within the characteristics of the original trial and
appropriately sharing the evidence as well as the uncertainties, it is reasonable to imple-
ment a LDCT lung cancer screening program for smokers and former smokers. Long-
lasting resources and quality controls are, of course, prerequisites.
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